Pharmacologic Neuroprotection in Experimental Spinal Cord Ischemia
- 1 January 2001
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Neurosurgical Anesthesiology
- Vol. 13 (1) , 3-12
- https://doi.org/10.1097/00008506-200101000-00002
Abstract
Various surgical procedures may cause temporary interruption of spinal cord blood supply and may result in irreversible ischemic injury and neurological deficits. The cascade of events that leads to neuronal death following ischemia may be amenable to pharmacological manipulations that aim to increase the tolerable duration of ischemia. Many agents have been evaluated in experimental spinal cord ischemia (SCI). In order to investigate whether an agent is available that justifies clinical evaluation, the literature on pharmacological neuroprotection in experimental SCI was systematically reviewed to assess the neuroprotective efficacy of the various agents. In addition, the strength of the evidence for neuroprotection was investigated by analyzing the methodology. The authors used a systematic review to conduct this evaluation. The included studies were analyzed for neuroprotection and methodology. In order to be able to compare the various agents for neuroprotective efficacy, relative risks and confidence intervals were calculated from the data in the results sections. A total of 103 studies were included. Seventy-nine different agents were tested. Only 14 of the agents tested did not afford protection at all. A large variation was observed in the experimental models to produce SCI. This variation limited comparison of the individual agents. In 48 studies involving 31 single agents, the relative risks and confidence intervals could be calculated. An analysis of the methodology revealed poor temperature management and lack of statistical power in the majority of the 103 studies. The results suggest that numerous agents may protect the spinal cord from transient ischemia. However, poor temperature management and lack of statistical power severely weakened the evidence. Consequently, clinical evaluation of pharmacological neuroprotection in surgical procedures that carry a risk of ischemic spinal cord damage is not justified on the basis of this study.Keywords
This publication has 109 references indexed in Scilit:
- Selective protection of gray and white matter during spinal cord ischemic injury11This article has been selected for the open discussion forum on the STS Web site: http:/www.Sts.org/section/atsdiscussion/The Annals of Thoracic Surgery, 1999
- Prevention of spinal cord injury after transient aortic clamping with tissue factor pathway inhibitorSurgery, 1996
- Effect of gamma-aminobutyric acid modulation on neuronal ischemia in rabbits.Stroke, 1994
- Diaspirin cross-linked hemoglobin improves neurological outcome following reversible but not irreversible CNS ischemia in rabbits.Stroke, 1994
- Paraplegia following thoracic aortic cross-clamping in dogs. No difference in neurological outcome with a barbiturate versus isoflurane.Stroke, 1993
- Effects of flunarizine on neurological recovery and spinal cord blood flow in experimental spinal cord ischemia in rabbits.Stroke, 1993
- Delayed therapy of experimental ischemia with competitive N-methyl-D-aspartate antagonists in rabbits.Stroke, 1993
- Effects of dichloroacetate in spinal stroke in the rabbitLife Sciences, 1987
- Evaluation of the calcium channel antagonist nimodipine in experimental spinal cord ischemiaJournal of Neurosurgery, 1984
- Comparison of naloxone and a δ-selective antagonist in experimental spinal strokeLife Sciences, 1983